| Year |
Citation |
Score |
| 2024 |
Modak RV, de Oliveira Rebola KG, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz SE, Eide CA, Wu G, Laderas T, Nechiporuk T, Gritsenko MA, Hansen JR, Hutchinson C, Gosline SJC, Piehowski P, ... ... Tyner JW, et al. Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38451486 DOI: 10.1158/1078-0432.CCR-23-2654 |
0.311 |
|
| 2024 |
Mohanty V, Baran N, Huang Y, Ramage CL, Cooper LM, He S, Iqbal R, Daher M, Tyner JW, Mills GB, Konopleva M, Chen K. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. Biorxiv : the Preprint Server For Biology. PMID 38352538 DOI: 10.1101/2024.01.27.577579 |
0.327 |
|
| 2023 |
Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. American Journal of Hematology. PMID 37815132 DOI: 10.1002/ajh.27096 |
0.444 |
|
| 2023 |
Eide CA, Kurtz SE, Kaempf A, Long N, Joshi SK, Nechiporuk T, Huang A, Dibb CA, Taylor A, Bottomly D, McWeeney SK, Minnier J, Lachowiez CA, Saultz JN, Swords RT, ... ... Tyner JW, et al. Clinical Correlates of Venetoclax-based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. PMID 37698624 DOI: 10.1158/2643-3230.BCD-23-0014 |
0.531 |
|
| 2023 |
Yashar WM, Curtiss BM, Coleman DJ, VanCampen J, Kong G, Macaraeg J, Estabrook J, Demir E, Long N, Bottomly D, McWeeney SK, Tyner JW, Druker BJ, Maxson JE, Braun TP. Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research : McR. PMID 36976323 DOI: 10.1158/1541-7786.MCR-22-0745 |
0.553 |
|
| 2022 |
Summers RJ, Jain J, Vasileiadi E, Smith B, Chimenti ML, Yeung TY, Kelvin J, Wang X, Frye SV, Earp HS, Tyner JW, Dreaden EC, DeRyckere D, Graham DK. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14. PMID 36551626 DOI: 10.3390/cancers14246142 |
0.307 |
|
| 2022 |
Lachowiez CA, Long N, Saultz JN, Gandhi A, Newell LF, Hayes-Lattin B, Maziarz RT, Leonard J, Bottomly D, McWeeney SK, Dunlap J, Press RD, Meyers G, Swords R, Cook R, ... Tyner JW, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Advances. PMID 36441905 DOI: 10.1182/bloodadvances.2022009010 |
0.376 |
|
| 2022 |
Rosenberg MW, Savage SL, Eide CA, Reister Schultz A, Cook RJ, Press RD, Rempfer C, Eickelberg G, Wilmot B, McWeeney SK, Tyner JW, Druker BJ, Tognon CE. Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia. Cold Spring Harbor Molecular Case Studies. 8. PMID 36307214 DOI: 10.1101/mcs.a006218 |
0.497 |
|
| 2022 |
Gosline SJC, Tognon C, Nestor M, Joshi S, Modak R, Damnernsawad A, Posso C, Moon J, Hansen JR, Hutchinson-Bunch C, Pino JC, Gritsenko MA, Weitz KK, Traer E, Tyner J, et al. Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. Clinical Proteomics. 19: 30. PMID 35896960 DOI: 10.1186/s12014-022-09367-9 |
0.5 |
|
| 2022 |
Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, ... ... Tyner JW, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. PMID 35868306 DOI: 10.1016/j.ccell.2022.07.002 |
0.458 |
|
| 2022 |
Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, Lo P, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia. Molecular Cancer Therapeutics. PMID 35499387 DOI: 10.1158/1535-7163.MCT-21-0832 |
0.544 |
|
| 2022 |
Vigoda M, Mathieson C, Evans N, Hale C, Jennings J, Lucero O, Jeng S, Bottomly D, Clayburgh D, Andersen P, Li R, Petrisor D, Tyner JW, McWeeney S, Kulesz-Martin M. Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. Cancer Biology & Therapy. 23: 310-318. PMID 35343367 DOI: 10.1080/15384047.2022.2055420 |
0.321 |
|
| 2022 |
Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, Nechiporuk T, Shouse G, Danilova OV, Bottomly D, McWeeney SK, Tyner JW, Kurtz SE, Danilov AV. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death & Disease. 13: 246. PMID 35296646 DOI: 10.1038/s41419-022-04684-1 |
0.367 |
|
| 2022 |
Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness BG, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research. PMID 35195258 DOI: 10.1158/0008-5472.CAN-21-3695 |
0.464 |
|
| 2022 |
Kurtz SE, Eide CA, Kaempf A, Long N, Bottomly D, Nikolova O, Druker BJ, McWeeney SK, Chang BH, Tyner JW, Agarwal A. Associating Drug Sensitivity with Differentiation Status Identifies Effective Combinations for Acute Myeloid Leukemia. Blood Advances. PMID 35078224 DOI: 10.1182/bloodadvances.2021006307 |
0.525 |
|
| 2021 |
Zhao H, Pomicter AD, Eiring AM, Franzini A, Ahmann J, Hwang JY, Senina AV, Helton B, Iyer SM, Yan D, Khorashad JS, Zabriskie MS, Agarwal A, Redwine HM, Bowler AD, ... ... Tyner JW, et al. MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. Blood. PMID 34780648 DOI: 10.1182/blood.2021011802 |
0.485 |
|
| 2021 |
Romine KA, Nechiporuk T, Bottomly D, Jeng S, McWeeney SK, Kaempf A, Corces MR, Majeti R, Tyner JW. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Blood Cancer Discovery. 2: 518-531. PMID 34568834 DOI: 10.1158/2643-3230.bcd-21-0012 |
0.322 |
|
| 2021 |
Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, ... ... Tyner JW, et al. TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337. PMID 34504101 DOI: 10.1038/s41467-021-25622-3 |
0.31 |
|
| 2021 |
Shomali W, Damnernsawad A, Theparee T, Sampson D, Morrow Q, Yang F, Fernandez-Pol S, Press RD, Zehnder JL, Tyner JW, Gotlib JR. A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood Advances. PMID 34496019 DOI: 10.1182/bloodadvances.2021004237 |
0.34 |
|
| 2021 |
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, ... ... Tyner JW, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood. PMID 34482403 DOI: 10.1182/blood.2021011354 |
0.438 |
|
| 2021 |
White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, et al. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology. 5: 71. PMID 34302041 DOI: 10.1038/s41698-021-00209-9 |
0.436 |
|
| 2021 |
Leonard J, Wolf JS, Degnin M, Eide CA, LaTocha D, Lenz K, Wilmot B, Mullighan CG, Loh M, Hunger SP, Druker BJ, Loriaux MM, Tyner JW, Chang BH. Aurora A kinase as a target for therapy in rearranged acute lymphoblastic leukemia. Haematologica. PMID 34233449 DOI: 10.3324/haematol.2021.278692 |
0.463 |
|
| 2021 |
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, ... ... Tyner JW, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. PMID 34171263 DOI: 10.1016/j.ccell.2021.06.003 |
0.495 |
|
| 2021 |
Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, ... ... Tyner JW, et al. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Research. PMID 33707228 DOI: 10.1101/gr.269233.120 |
0.441 |
|
| 2021 |
Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, ... ... Tyner JW, et al. An expanded universe of cancer targets. Cell. 184: 1142-1155. PMID 33667368 DOI: 10.1016/j.cell.2021.02.020 |
0.408 |
|
| 2021 |
Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, ... ... Tyner JW, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery. PMID 33563661 DOI: 10.1158/2159-8290.CD-20-0564 |
0.389 |
|
| 2021 |
Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI. Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Advances. 5: 711-724. PMID 33560385 DOI: 10.1182/bloodadvances.2020003429 |
0.386 |
|
| 2020 |
Damnernsawad A, Bottomly D, Kurtz SE, Eide CA, McWeeney SK, Tyner JW, Nechiporuk T. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia. Haematologica. PMID 33375770 DOI: 10.3324/haematol.2020.257964 |
0.392 |
|
| 2020 |
Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nature Cancer. 1: 826-839. PMID 33123685 DOI: 10.1038/s43018-020-0103-x |
0.346 |
|
| 2020 |
Leonard J, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd KH, Druker BJ, Tyner JW, Chang BH, Lind EF. Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. Blood. PMID 32898857 DOI: 10.1182/Blood.2020005655 |
0.583 |
|
| 2020 |
Rosenberg MW, Watanabe-Smith K, Tyner JW, Tognon CE, Druker BJ, Borate U. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. Oncotarget. 11: 2807-2818. PMID 32754299 DOI: 10.18632/Oncotarget.27656 |
0.583 |
|
| 2020 |
Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H, Loriaux MM, ... ... Tyner JW, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 32513686 DOI: 10.1073/Pnas.1916206117 |
0.468 |
|
| 2020 |
Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ. ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. PMID 32366937 DOI: 10.1038/S41375-020-0844-7 |
0.516 |
|
| 2020 |
Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare M, Druker BJ, Tognon CE. Discovery and Characterization of Targetable NTRK Point Mutations in Hematologic Neoplasms. Blood. PMID 32315394 DOI: 10.1182/Blood.2019003691 |
0.569 |
|
| 2020 |
Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV, Tyner JW. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 32094466 DOI: 10.1038/S41375-020-0764-6 |
0.555 |
|
| 2019 |
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, ... ... Tyner JW, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900895. PMID 31880950 DOI: 10.1200/Jco.19.00895 |
0.549 |
|
| 2019 |
Tyner JW, Bottomly D, Wilmot B, McWeeney S. What do functional genomics tell us about pathogenesis of AML? Best Practice & Research. Clinical Haematology. 32: 101101. PMID 31779979 DOI: 10.1016/J.Beha.2019.101101 |
0.365 |
|
| 2019 |
Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, et al. Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3: 3201-3213. PMID 31698451 DOI: 10.1182/Bloodadvances.2019000641 |
0.504 |
|
| 2019 |
Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, et al. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. Plos One. 14: e0223639. PMID 31596908 DOI: 10.1371/Journal.Pone.0223639 |
0.376 |
|
| 2019 |
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, ... ... Tyner JW, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. PMID 31543464 DOI: 10.1016/J.Ccell.2019.08.004 |
0.595 |
|
| 2019 |
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Tyner JW, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/Blood.2019000611 |
0.415 |
|
| 2019 |
Sun QY, Ding LW, Johnson K, Zhou S, Tyner JW, Yang H, Doan NB, Said JW, Xiao JF, Loh XY, Ran XB, Venkatachalam N, Lao Z, Chen Y, Xu L, et al. SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene. PMID 31332289 DOI: 10.1038/S41388-019-0865-8 |
0.381 |
|
| 2019 |
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, ... Tyner JW, et al. The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells. Cancer Discovery. PMID 31048320 DOI: 10.1158/2159-8290.Cd-19-0125 |
0.545 |
|
| 2019 |
Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30924767 DOI: 10.7554/Elife.47174 |
0.466 |
|
| 2019 |
Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/Elife.40033 |
0.654 |
|
| 2019 |
Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, ... ... Tyner JW, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications. 10: 244. PMID 30651561 DOI: 10.1038/S41467-018-08263-X |
0.585 |
|
| 2019 |
Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research. PMID 30642575 DOI: 10.1016/J.Leukres.2018.11.010 |
0.478 |
|
| 2019 |
Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica. PMID 30606790 DOI: 10.3324/Haematol.2018.201483 |
0.441 |
|
| 2019 |
Bottomly D, Long N, Yang F, Lee T, Borate U, Wilmot B, DuVall AS, Monteblanco A, Thiel-Klare K, Dewson G, Press RD, Tognon CE, Druker BJ, Tyner JW, McWeeney SK, et al. Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort Blood. 134: 1407-1407. DOI: 10.1182/Blood-2019-132224 |
0.518 |
|
| 2019 |
Eide CA, Zabriskie MS, Savage SL, Antelope O, Vellore NA, Than H, Reister Schultz A, Clair PM, Bowler AD, Pomicter AD, Yan D, Senina AV, Wang Q, Kelley TW, Szankasi P, ... ... Tyner JW, et al. Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants Blood. 134: 188-188. DOI: 10.1182/Blood-2019-131781 |
0.537 |
|
| 2019 |
Eide CA, Kurtz SE, Kaempf A, Long N, Leonard J, Chang BH, Mori M, Druker BJ, Tyner JW. Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia Blood. 134: 3950-3950. DOI: 10.1182/Blood-2019-131288 |
0.548 |
|
| 2019 |
Nechiporuk T, Damnernsawad A, Bottomly D, Morrow Q, Choi S, Beer S, Kurtz SE, McWeeney SK, Tyner JW. Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib Blood. 134: 1395-1395. DOI: 10.1182/Blood-2019-129117 |
0.426 |
|
| 2019 |
Damnernsawad A, Nechiporuk T, Bottomly D, Kurtz SE, Eide CA, McWeeney SK, Tyner JW. Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia Blood. 134: 2557-2557. DOI: 10.1182/Blood-2019-128877 |
0.456 |
|
| 2019 |
Giacopelli B, Wang M, Cleary AC, Wu Y, Schultz AR, Blachly JS, Eisfeld A, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC. DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia Blood. 134: 1413-1413. DOI: 10.1182/Blood-2019-126212 |
0.459 |
|
| 2019 |
Kurtz SE, Eide CA, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Tyner JW. Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia Blood. 134: 878-878. DOI: 10.1182/Blood-2019-126020 |
0.484 |
|
| 2019 |
Joshi SK, Bisson W, Qian K, Huang A, Watanabe-Smith K, Tyner JW, Davare MA, McWeeney SK, Tognon CE, Druker BJ. Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia Blood. 134: 1256-1256. DOI: 10.1182/Blood-2019-125908 |
0.562 |
|
| 2019 |
Moshofsky KB, Cho HJ, Kosaka Y, Newman MT, Tyner JW, Lind EF. Abstract 508: Combined MEK and PD-1 inhibition in acute myeloid leukemia: Effect on cell proliferation and phenotype Immunology. DOI: 10.1158/1538-7445.Sabcs18-508 |
0.345 |
|
| 2019 |
Damnernsawad A, Nechiporuk T, Kurtz SE, Horton WR, Nikolova O, McWeeney SK, Tyner JW. Abstract 4763: Genome-wide CRISPR screening identifies TSC1 as a regulator of sorafenib resistance in acute myeloid leukemia Cancer Research. 79: 4763-4763. DOI: 10.1158/1538-7445.Sabcs18-4763 |
0.505 |
|
| 2019 |
Lawrence R, Thurman R, Biechele T, Tognon C, Savage S, Schultz AR, Tyner J, Arthur W. Abstract 4546: Functional cell surface proteomics of acute myeloid leukemia enables predictive modeling of antibody-drug conjugate cytotoxicity Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4546 |
0.314 |
|
| 2019 |
Piehowski PD, McDermott JE, Hansen JR, Savage SL, Tognon CE, Agarwal A, Tyner JW, Druker BJ, Rodland KD. Abstract 4538: Global and phosphoproteomic analysis of AML cell line response to phosphatase inhibitor treatment Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4538 |
0.519 |
|
| 2019 |
Romine KA, Kurtz S, Tyner J. Abstract 333: BRD4 inhibitor-resistant acute myeloid leukemia cells develop new sensitivities and resistances to small-molecule inhibitors identifiable through high-capacity drug screening Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-333 |
0.402 |
|
| 2019 |
Nechiporuk T, Kurtz SE, Nikolova O, d'Almeida A, Watanabe-Smith K, Rosenberg M, Druker B, Tyner JW, McWeeney SK. Abstract 325: A genome-wide CRISPR screen on AML cells reveals the TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-325 |
0.501 |
|
| 2019 |
Vijay V, Meacham A, Katzell L, Winer A, Terrell J, Archibald V, Bubenik J, Riva A, Boatwright J, Tognon C, Tyner J, Druker B, Cogle C. Abstract 3042: Splicing repressorHNRNPCis an indispensable and 'druggable' target in acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3042 |
0.499 |
|
| 2019 |
Joshi SK, Christy S, Ribeiro RS, McWeeney S, Tyner JW, Tognon CE, Druker BJ, Traer E. Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia Cancer Research. 79: 926-926. DOI: 10.1158/1538-7445.Am2019-926 |
0.6 |
|
| 2019 |
Zhang H, Local A, Tyner JW, Kurtz SE, Wilmot B, Mcweeney S, Druker BJ, Howell SB, Rice WG. Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients Cancer Research. 79: 1323-1323. DOI: 10.1158/1538-7445.Am2019-1323 |
0.53 |
|
| 2018 |
Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, ... ... Tyner JW, et al. CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. PMID 30425048 DOI: 10.1182/Blood-2018-03-838946 |
0.378 |
|
| 2018 |
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/S41586-018-0623-Z |
0.478 |
|
| 2018 |
Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene. PMID 30242244 DOI: 10.1038/S41388-018-0508-5 |
0.411 |
|
| 2018 |
Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 30082821 DOI: 10.1038/S41375-018-0225-7 |
0.499 |
|
| 2018 |
Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Science Signaling. 11. PMID 30018082 DOI: 10.1126/Scisignal.Aao5617 |
0.39 |
|
| 2018 |
Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9: 24576-24589. PMID 29872489 DOI: 10.18632/Oncotarget.25191 |
0.523 |
|
| 2018 |
Ouyang X, Barling A, Lesch A, Tyner JW, Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA, McWeeney SK, Kulesz-Martin M. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. Cancer Biology & Therapy. 1-37. PMID 29856687 DOI: 10.1080/15384047.2018.1451285 |
0.342 |
|
| 2018 |
Chow M, Gao L, MacManiman JD, Bicocca VT, Chang BH, Alumkal JJ, Tyner JW. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. Oncogene. PMID 29849118 DOI: 10.1038/s41388-018-0299-8 |
0.312 |
|
| 2018 |
Jamalpour M, Li X, Gustafsson K, Tyner JW, Welsh M. Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 40: 1010428318771472. PMID 29792386 DOI: 10.1177/1010428318771472 |
0.307 |
|
| 2018 |
Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK. Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. Haematologica. PMID 29567769 DOI: 10.3324/Haematol.2018.190926 |
0.446 |
|
| 2018 |
Rosenberg M, Fan G, Watanabe-Smith K, Tognon C, Druker BJ, Tyner J, Loriaux M. Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen. Journal of Clinical Oncology. 36: 7025-7025. DOI: 10.1200/Jco.2018.36.15_Suppl.7025 |
0.559 |
|
| 2018 |
Klug LR, Bannon A, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke J, Musil L, Fletcher JA, Tyner J, Heinrich MC. LMTK3 to regulate the translation of oncogenic KIT in GIST regardless of imatinib sensitivity. Journal of Clinical Oncology. 36: 11535-11535. DOI: 10.1200/Jco.2018.36.15_Suppl.11535 |
0.392 |
|
| 2018 |
Dao K, Collins RH, Cortes JE, Deininger MW, Druker BJ, Gotlib JR, Macey TA, Oh ST, Tyner JW, Winton EF. Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Blood. 132: 350-350. DOI: 10.1182/Blood-2018-99-119476 |
0.516 |
|
| 2018 |
Leonard J, Kosaka Y, Newman MT, Lamble AJ, Malla P, Druker BJ, Tyner JW, Chang BH, Lind EF. Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia Blood. 132: 1547-1547. DOI: 10.1182/Blood-2018-99-119409 |
0.51 |
|
| 2018 |
Leonard J, Kosaka Y, Malla P, Hayes-Lattin B, Lamble AJ, Druker BJ, Tyner JW, Chang BH, Lind EF. T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia Blood. 132: 2694-2694. DOI: 10.1182/Blood-2018-99-119301 |
0.567 |
|
| 2018 |
Brady LK, Soong D, Lind EF, Kosaka Y, Lamble AJ, Schaffer M, Hodkinson BP, Lefave C, Laderas T, McWeeney SK, Adams H, Abraham Y, Safabakhsh P, Tyner JW, Druker BJ, et al. Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness Blood. 132: 2750-2750. DOI: 10.1182/Blood-2018-99-118424 |
0.542 |
|
| 2018 |
Kurtz SE, Eide CA, Dubey NP, Kaempf A, McWeeney SK, Tognon CE, Mori M, Druker BJ, Tyner JW, Agarwal A. Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells Blood. 132: 2726-2726. DOI: 10.1182/Blood-2018-99-117537 |
0.591 |
|
| 2018 |
Eide CA, Kurtz SE, Kaempf A, Tognon CE, Mori M, Gordon MJ, Tyner JW, Danilov AV, Druker BJ. Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias Blood. 132: 214-214. DOI: 10.1182/Blood-2018-99-117468 |
0.582 |
|
| 2018 |
Zhang H, Local A, Benbatoul K, Folger P, Sheng S, McLaughlin T, Danilov AV, Kurtz SE, Tyner JW, Howell S, Rice WG. CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells Blood. 132: 3503-3503. DOI: 10.1182/Blood-2018-99-117285 |
0.433 |
|
| 2018 |
Chang BH, Leonard J, Wolf J, Degnin M, Lenz K, Wilmot B, Mullighan CG, Loh ML, Hunger SP, Tyner JW, Druker BJ. Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia Blood. 132: 4026-4026. DOI: 10.1182/Blood-2018-99-115706 |
0.552 |
|
| 2018 |
Tyner JW, Druker BJ, Tognon CE, Kurtz SE, Drusbosky LM, Sahu D, Vidva R, Kapoor S, Azam H, Kumar R, Chickdipatti PG, Raveendaran NT, Gopi RP, Abbasi T, Vali S, et al. Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 132: 1541-1541. DOI: 10.1182/Blood-2018-99-115678 |
0.556 |
|
| 2018 |
Schultz AR, Jacob T, Eide CA, Savage SL, Mori M, Tyner JW, Tognon CE, Vu TQ, Druker BJ. Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging Blood. 132: 4248-4248. DOI: 10.1182/Blood-2018-99-115387 |
0.526 |
|
| 2018 |
Tyner JW, Druker BJ, Kurtz SE, Tognon CE, Drusbosky LM, Vidva R, Narvekar Y, Agrawal AK, Gera S, Prasad SA, Shyamasundar VP, Tunwer GS, Abbasi T, Vali S, Cogle CR. Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 132: 1540-1540. DOI: 10.1182/Blood-2018-99-115284 |
0.577 |
|
| 2018 |
Moses BS, Fox J, Chen X, McCullough S, Tran SN, Kirkpatrick A, Kumar K, Tyner JW, Posner GH, Civin CI. The 3-Drug Combination Treatment ART838, ABT199 Plus Sorafenib Is Effective Against AML Xenografts, Possibly Via Cooperative Targeting of MCL1 Blood. 132: 4044-4044. DOI: 10.1182/Blood-2018-99-113040 |
0.413 |
|
| 2018 |
White BS, Khan SA, Ammad-ud-din M, Potdar S, Mason MJ, Tognon CE, Druker BJ, Heckman CA, Kallioniemi O, Kurtz SE, Porkka K, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML Blood. 132: 2763-2763. DOI: 10.1182/Blood-2018-99-111916 |
0.514 |
|
| 2018 |
Zhang H, Wilmot B, Bottomly D, Kurtz SE, Eide CA, Damnernsawad A, Romine K, Patel S, Druker BJ, Mcweeney SK, Majeti R, Tyner JW. Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment Blood. 132: 175-175. DOI: 10.1182/Blood-2018-175 |
0.574 |
|
| 2018 |
Kurtz SE, Watanabe-Smith K, Bottomly D, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples Cancer Research. 78: 791-791. DOI: 10.1158/1538-7445.Am2018-791 |
0.622 |
|
| 2018 |
White BS, Khan SA, Ammad-ud-din M, Potdar S, Mason MJ, Tognon CE, Druker BJ, Heckman CA, Kallioniemi OP, Kurtz SE, Porkka K, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia Cancer Research. 78: 3883-3883. DOI: 10.1158/1538-7445.Am2018-3883 |
0.502 |
|
| 2018 |
Tron AE, Belmonte MA, Criscione S, Clark EA, Gangl E, Gibbons FD, Tyner JW, Kurtz SE, Ye Q, Hird AW, Schuller A, Secrist JP. Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia Cancer Research. 78: 302-302. DOI: 10.1158/1538-7445.Am2018-302 |
0.414 |
|
| 2017 |
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/Bloodadvances.2017005694 |
0.529 |
|
| 2017 |
Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, et al. A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. PMID 29284681 DOI: 10.3324/Haematol.2017.165282 |
0.435 |
|
| 2017 |
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, ... ... Tyner JW, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. PMID 28784769 DOI: 10.1073/Pnas.1703094114 |
0.497 |
|
| 2017 |
Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. Plos One. 12: e0179558. PMID 28719608 DOI: 10.1371/Journal.Pone.0179558 |
0.412 |
|
| 2017 |
Tyner JW. Kinase Inhibitor Screening in Myeloid Malignancies. Hematology/Oncology Clinics of North America. 31: 693-704. PMID 28673396 DOI: 10.1016/j.hoc.2017.04.004 |
0.311 |
|
| 2017 |
Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW. Recurrent cyclin D2 mutations in myeloid neoplasms. Leukemia. 31: 2005-2008. PMID 28630439 DOI: 10.1038/Leu.2017.195 |
0.399 |
|
| 2017 |
Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, et al. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. Oncotarget. PMID 28412732 DOI: 10.18632/Oncotarget.15410 |
0.408 |
|
| 2017 |
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, et al. BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. PMID 28356518 DOI: 10.1073/Pnas.1609758114 |
0.443 |
|
| 2017 |
Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Reports. 18: 3204-3218. PMID 28355571 DOI: 10.1016/J.Celrep.2017.03.018 |
0.505 |
|
| 2017 |
Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, ... Tyner JW, et al. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. PMID 28186983 DOI: 10.18632/Oncotarget.15146 |
0.543 |
|
| 2017 |
Borate U, Norris BA, Lo P, Tognon C, Tyner J, Spurgeon S. Identification of targeted therapies for rare adult mature t-cell leukemia using functional ex vivo screening of primary patient samples. American Journal of Hematology. PMID 28181280 DOI: 10.1182/Blood.V128.22.4720.4720 |
0.447 |
|
| 2017 |
Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, ... ... Tyner JW, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug resistant ALL. Blood. PMID 28122742 DOI: 10.1182/Blood-2016-09-738070 |
0.425 |
|
| 2017 |
Klug LR, Tyner J, Heinrich MC. LMTK3 as a novel regulator of oncogenic KIT in KIT-mutant cancers. Journal of Clinical Oncology. 35: 11044-11044. DOI: 10.1200/Jco.2017.35.15_Suppl.11044 |
0.497 |
|
| 2017 |
Zhang H, Maxson JE, Watanabe-Smith KM, Coblentz C, Tyner JW. Distinct Mechanisms of Receptor Activation Are Associated with CSF3R Gain-of-Function Mutations Blood. 130: 4985-4985. DOI: 10.1182/Blood.V130.Suppl_1.4985.4985 |
0.314 |
|
| 2017 |
Kurtz SE, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples Blood. 130: 4626-4626. DOI: 10.1182/Blood.V130.Suppl_1.4626.4626 |
0.635 |
|
| 2017 |
Drusbosky LM, Turcotte M, Castillo P, Vidva R, Gera S, Sauban M, Bhargav P, Deep P, Kapoor S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, et al. Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study Blood. 130: 3909-3909. DOI: 10.1182/Blood.V130.Suppl_1.3909.3909 |
0.608 |
|
| 2017 |
Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3908-3908. DOI: 10.1182/Blood.V130.Suppl_1.3908.3908 |
0.581 |
|
| 2017 |
Drusbosky LM, Vidva R, Gera S, Das A, Tiwari KK, Joseph V, Mohapatra S, Lunkad N, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3907-3907. DOI: 10.1182/Blood.V130.Suppl_1.3907.3907 |
0.492 |
|
| 2017 |
Watanabe-Smith K, Rosenberg M, Bucy T, Tyner JW, Borate U. Factors Predicting Response and Resistance to Midostaurin in FLT3 Positive and FLT3 Negative AML in 483 Primary AML Patient Samples Blood. 130: 296-296. DOI: 10.1182/Blood.V130.Suppl_1.296.296 |
0.472 |
|
| 2017 |
Drusbosky LM, Hawkins KE, Leather HL, Murthy HS, Farhadfar N, Wingard JR, Norkin M, Brown RA, Hiemenz JW, Castillo P, Horn BN, Kumar A, Singh NK, Kumar C, Vasista S, ... ... Tyner JW, et al. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing Blood. 130: 2707-2707. DOI: 10.1182/Blood.V130.Suppl_1.2707.2707 |
0.468 |
|
| 2017 |
Hodgson G, Johannessen L, Rajagopal N, Hu S, Orlando D, Eaton M, McKeown M, Tyner JW, Kurtz SE, Sprott K, Fritz C, Tomaso ED. Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia Blood. 130: 2651-2651. DOI: 10.1182/Blood.V130.Suppl_1.2651.2651 |
0.335 |
|
| 2017 |
Kurtz SE, Eide CA, Kaempf A, Savage SL, Schultz AMR, Wilmot B, Mcweeney S, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia Blood. 130: 2068-2068. DOI: 10.1182/Blood.V130.Suppl_1.2068.2068 |
0.542 |
|
| 2017 |
Eide CA, Kurtz SE, Kaempf A, Park A, Rofelty A, Wilmot B, Bottomly D, McWeeney SK, Tognon CE, Mori M, Tyner JW, Druker BJ. Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations Blood. 130: 1422-1422. DOI: 10.1182/Blood.V130.Suppl_1.1422.1422 |
0.558 |
|
| 2017 |
Kurtz SE, Wilmot B, McWeeney S, Vellanki A, Local A, Benbatoul K, Folger P, Sheng S, Zhang H, Howell SB, Rice WG, Druker BJ, Tyner JW. Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes Clinical Cancer Research. 23: 44-44. DOI: 10.1158/1557-3265.Hemmal17-44 |
0.619 |
|
| 2017 |
Ouyang X, Barling A, Lesch A, Tyner J, Jeng S, Zheng C, Courtneidge SA, McWeeney S, Kulesz-Martin M. Abstract 78: Inhibiting anaplastic lymphoma kinase (ALK) overcomes epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) patient-derived models Clinical Cancer Research. 23: 78-78. DOI: 10.1158/1557-3265.Aacrahns17-78 |
0.469 |
|
| 2017 |
Hird AW, Secrist JP, Adam A, Belmonte MA, Gangl E, Gibbons F, Hargreaves D, Johannes JW, Kazmirski SL, Kettle JG, Kurtz SE, Lamb ML, Packer MJ, Peng B, Stewart CR, ... Tyner JW, et al. Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ddt01-02 |
0.399 |
|
| 2017 |
Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Kükenshöner T, Hantschel O, Bottomly D, Wilmot B, McWeeney SK, Tyner JW. Abstract 532: Identification of unpaired cysteine-mediated gain and loss of function CSF3R extracellular mutations Cancer Research. 77: 532-532. DOI: 10.1158/1538-7445.Am2017-532 |
0.314 |
|
| 2017 |
Kanojia D, Garg M, Martinez J, Anand MT, Luty SB, Doan NB, Said JW, Tyner JW, Koeffler HP. Abstract 4188: Multitargeted tyrosine kinase inhibitor identified as potential therapeutic intervention for liposarcoma using high-throughput profiling Cancer Research. 77: 4188-4188. DOI: 10.1158/1538-7445.Am2017-4188 |
0.356 |
|
| 2017 |
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Yang H, Ding L, Jiang Y, Tyner JW, Ching J, Kovalik J, et al. Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic target Cancer Research. 77: 2569-2569. DOI: 10.1158/1538-7445.Am2017-2569 |
0.31 |
|
| 2017 |
Moses BS, Fox JM, Chen X, Tyner JW, Posner GH, Bailey P, Civin CI. Abstract 2023: Artemisinins enhanced the antileukemic efficacy of BCL2 inhibitors Cancer Research. 77: 2023-2023. DOI: 10.1158/1538-7445.Am2017-2023 |
0.318 |
|
| 2017 |
Ouyang X, Barling A, Lesch A, Tyner J, Jeng S, Zheng C, Courtneidge SA, McWeeney S, Kulesz-Martin M. Abstract 1212: Co-targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase overcomes EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models Cancer Research. 77: 1212-1212. DOI: 10.1158/1538-7445.Am2017-1212 |
0.387 |
|
| 2017 |
Edwards DK, Javidi-Sharifi N, Rofelty A, Gordon M, Roth-Carter R, Tardi P, Mayer L, Tyner JW. Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD Cancer Research. 77: 1087-1087. DOI: 10.1158/1538-7445.Am2017-1087 |
0.479 |
|
| 2017 |
Ouyang X, Barling A, Tyner J, McWeeney S, Kulesz-Martin M. 704 Co-targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) overcomes EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models Journal of Investigative Dermatology. 137: S121. DOI: 10.1016/J.Jid.2017.02.727 |
0.388 |
|
| 2017 |
McClanahan D, Barling A, Ouyang X, Searles R, Tyner J, McWeeney S, Kulesz-Martin M. 087 Inhibitor assays to determine effective drugs and their targets in cutaneous squamous cell carcinoma Journal of Investigative Dermatology. 137: S15. DOI: 10.1016/J.Jid.2017.02.101 |
0.342 |
|
| 2017 |
Jamalpour M, Gustafsson K, Tyner J, Welsh M. Disparate effects of SHB-deficiency on disease characteristics in murine models of myeloid, B cell and T cell leukemia Experimental Hematology. 53: S95. DOI: 10.1016/J.Exphem.2017.06.221 |
0.342 |
|
| 2017 |
Zhang Q, Han L, Pan R, Shi C, Jeremy R, John Ma MC, Kurtz S, Mu H, Ruvolo VR, Ma H, Mi Y, Tyner J, Anthony L, Davis RE, Andreeff M, et al. MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models Clinical Lymphoma Myeloma and Leukemia. 17: S2. DOI: 10.1016/J.Clml.2017.09.025 |
0.372 |
|
| 2016 |
Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood. PMID 28028025 DOI: 10.1182/Blood-2016-10-695981 |
0.395 |
|
| 2016 |
Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research. 53: 39-49. PMID 28013106 DOI: 10.1016/J.Leukres.2016.12.002 |
0.418 |
|
| 2016 |
Richard NP, Pippa R, Cleary MM, Puri A, Tibbitts D, Mahmood S, Christensen DJ, Jeng S, McWeeney S, Thomas Look A, Chang BH, Tyner JW, Vitek MP, Odero MD, Sears R, et al. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget. PMID 27705940 DOI: 10.18632/Oncotarget.12394 |
0.445 |
|
| 2016 |
Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Research. PMID 27671675 DOI: 10.1158/0008-5472.Can-15-3569 |
0.568 |
|
| 2016 |
DeRyckere D, Lee Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GD, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649555 DOI: 10.1158/1078-0432.Ccr-16-1330 |
0.436 |
|
| 2016 |
Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Science Translational Medicine. 8: 354ra114. PMID 27582059 DOI: 10.1126/Scitranslmed.Aaf5309 |
0.593 |
|
| 2016 |
Agarwal A, Tyner JW. RNAi Screening of Leukemia Cells Using Electroporation. Methods in Molecular Biology (Clifton, N.J.). 1470: 85-94. PMID 27581286 DOI: 10.1007/978-1-4939-6337-9_7 |
0.358 |
|
| 2016 |
Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Scientific Reports. 6: 28163. PMID 27320899 DOI: 10.1038/Srep28163 |
0.517 |
|
| 2016 |
Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, ... Tyner JW, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. PMID 27196599 DOI: 10.1136/Gutjnl-2016-311818 |
0.313 |
|
| 2016 |
Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A. Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia. Leukemia. PMID 27118405 DOI: 10.1038/Leu.2016.95 |
0.515 |
|
| 2016 |
Leonard JT, Raess PW, Dunlap J, Hayes-Lattin B, Tyner JW, Traer E. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. Journal of Hematology & Oncology. 9: 31. PMID 27036514 DOI: 10.1186/S13045-016-0258-1 |
0.431 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser K, Tognon C, Laderas T, McWeeney S, Loriaux M, Druker BJ, Tyner J, Lind E. Comprehensive characterization of VISTA expression in patients with acute myeloid leukemia. Journal of Clinical Oncology. 34: e14546-e14546. DOI: 10.1200/Jco.2016.34.15_Suppl.E14546 |
0.538 |
|
| 2016 |
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies Blood. 128: 836-836. DOI: 10.1182/Blood.V128.22.836.836 |
0.474 |
|
| 2016 |
Edwards DK, Javidi-Sharifi N, Rofelty A, Rosenfeld C, Roth-Carter R, Tardi P, Mayer L, Tyner JW. Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation Blood. 128: 5124-5124. DOI: 10.1182/Blood.V128.22.5124.5124 |
0.471 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser AK, Adams H, Tognon CE, Laderas T, McWeeney SK, Loriaux MM, Tyner JW, Druker BJ, Lind EF. Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia Blood. 128: 4056-4056. DOI: 10.1182/Blood.V128.22.4056.4056 |
0.522 |
|
| 2016 |
Spurgeon SE, Cook R, Traer E, Borate U, Maziarz RT, Tyner JW, Druker BJ, Macey T, Werth K, Junio B, Tognon CE, Mori M, Loriaux M. A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies Blood. 128: 4051-4051. DOI: 10.1182/Blood.V128.22.4051.4051 |
0.589 |
|
| 2016 |
Jenkins C, Luty SB, Maxson JE, Eide CA, Chang BH, Tyner JW. PTPN11 Mutations in JMML Confer Dasatinib Sensitivity in a TNK2-Dependent Manner Blood. 128: 3154-3154. DOI: 10.1182/Blood.V128.22.3154.3154 |
0.515 |
|
| 2016 |
Lamble A, Kosaka Y, Huang F, Sasser AK, Adams H, Tognon CE, Laderas T, McWeeney SK, Loriaux MM, Tyner JW, Druker BJ, Lind EF. Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia Blood. 128: 2829-2829. DOI: 10.1182/Blood.V128.22.2829.2829 |
0.519 |
|
| 2016 |
Leonard JT, Chang BH, Tyner JW, Hayes-Lattin B, Loriaux MM, Druker BJ, Borate U. Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia Blood. 128: 2811-2811. DOI: 10.1182/Blood.V128.22.2811.2811 |
0.585 |
|
| 2016 |
Eide CA, Savage SL, Heinrich MC, Reister Schultz AM, Tyner JW, Tognon CE, Druker BJ. Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia Blood. 128: 2747-2747. DOI: 10.1182/Blood.V128.22.2747.2747 |
0.61 |
|
| 2016 |
Zhang H, Reister Schultz A, Luty SB, Means S, David L, Klimek J, Bottomly D, Wilmot B, McWeeney S, Su Y, Tyner JW. Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential Blood. 128: 2735-2735. DOI: 10.1182/Blood.V128.22.2735.2735 |
0.385 |
|
| 2016 |
Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney SK, Druker BJ, Tyner JW. Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies Blood. 128: 2734-2734. DOI: 10.1182/Blood.V128.22.2734.2734 |
0.58 |
|
| 2016 |
Drusbosky L, Abbasi T, Vali S, Radhakrishnan S, Kumar Singh N, Usmani S, Parashar D, Vidva R, Druker BJ, Tognon CE, Lo P, Tyner JW, Cogle CR. A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study Blood. 128: 1713-1713. DOI: 10.1182/Blood.V128.22.1713.1713 |
0.537 |
|
| 2016 |
Eden CO, Edwards DK, Eide CA, Traer E, Tyner JW, McWeeney SK, Agarwal A. Cytokine-Mediated Inflammatory Pathways Promote Clonal Evolution and Disease Progression in Acute Myeloid Leukemia Blood. 128: 1688-1688. DOI: 10.1182/Blood.V128.22.1688.1688 |
0.362 |
|
| 2016 |
Leonard JT, Tyner JW, Rowley J, Loriaux MM, Druker BJ, Chang BH. Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway Blood. 128: 1583-1583. DOI: 10.1182/Blood.V128.22.1583.1583 |
0.572 |
|
| 2016 |
Eide CA, Bottomly D, Savage SL, White L, Wilmot B, Reister Schultz AM, Uchida KA, Agarwal A, Traer E, Beppu L, Sala-Torra O, Radich JP, Eickelberg G, Press RD, Loriaux MM, ... ... Tyner JW, et al. Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Blood. 128: 1119-1119. DOI: 10.1182/Blood.V128.22.1119.1119 |
0.61 |
|
| 2016 |
Traer E, Javidi-Sharifi N, Martinez J, English I, Dunlap J, Agarwal A, Kovacsovics TJ, Tyner JW, Wong M, Druker BJ. FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations Blood. 128: 1080-1080. DOI: 10.1182/Blood.V128.22.1080.1080 |
0.603 |
|
| 2016 |
Zhang Q, Han L, Shi C, Pan R, MA MCJ, Ryan J, Kurtz SE, Mu H, Ruvolo V, Ma H, Andreeff M, Mi Y, Tyner JW, Leverson J, Letai A, et al. Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Blood. 128: 101-101. DOI: 10.1182/Blood.V128.22.101.101 |
0.422 |
|
| 2016 |
Tyner JW. Abstract IA04: Functional genomics for discovery of pathogenic mechanisms of disease and novel therapies for hematologic malignancies Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pmsclingen15-Ia04 |
0.402 |
|
| 2016 |
Gordon M, Tardi P, Mayer LD, Tyner J. Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes Cancer Research. 76: 287-287. DOI: 10.1158/1538-7445.Am2016-287 |
0.318 |
|
| 2016 |
Eryildiz F, Tyner JW. Abstract 1265: Dysregulated tyrosine kinase Tyro3 signaling in acute myeloid leukemia Cancer Research. 76: 1265-1265. DOI: 10.1158/1538-7445.Am2016-1265 |
0.474 |
|
| 2015 |
Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. CurēUs. 7: e414. PMID 26870618 DOI: 10.7759/Cureus.414 |
0.569 |
|
| 2015 |
Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, ... ... Tyner JW, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.Can-15-0817 |
0.595 |
|
| 2015 |
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. PMID 26648538 DOI: 10.1038/Leu.2015.337 |
0.499 |
|
| 2015 |
Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, M T A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, ... ... Tyner JW, et al. Genomic landscape of liposarcoma. Oncotarget. PMID 26643872 DOI: 10.18632/Oncotarget.6464 |
0.36 |
|
| 2015 |
Dao KH, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015: 264-71. PMID 26637732 DOI: 10.1182/Asheducation-2015.1.264 |
0.401 |
|
| 2015 |
Lue HW, Cole B, Rao SA, Podalak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. PMID 26625308 DOI: 10.18632/Oncotarget.5971 |
0.445 |
|
| 2015 |
Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology. PMID 26573090 DOI: 10.1002/Ajh.24245 |
0.544 |
|
| 2015 |
Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide CA, Loriaux MM, Stevens EA, Tyner JW. The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26475333 DOI: 10.1158/1078-0432.Ccr-14-3100 |
0.383 |
|
| 2015 |
Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leukemia & Lymphoma. 1-22. PMID 26389776 DOI: 10.3109/10428194.2015.1094697 |
0.387 |
|
| 2015 |
Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget. PMID 26254279 DOI: 10.18632/Oncotarget.4214 |
0.559 |
|
| 2015 |
Viola S, Traer E, Huan J, Hornick NI, Tyner JW, Agarwal A, Loriaux M, Johnstone B, Kurre P. Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. British Journal of Haematology. PMID 26095727 DOI: 10.1111/Bjh.13551 |
0.356 |
|
| 2015 |
Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75: 2146-50. PMID 26032424 DOI: 10.1158/0008-5472.Can-14-1576 |
0.6 |
|
| 2015 |
Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nature Cell Biology. 17: 665-77. PMID 25915125 DOI: 10.1038/Ncb3158 |
0.405 |
|
| 2015 |
Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/S13045-015-0132-6 |
0.547 |
|
| 2015 |
Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Tyner JW, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003 |
0.561 |
|
| 2015 |
Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L, Mori S, Yang H, Tyner JW, Koeffler HP. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Molecular Oncology. 9: 889-905. PMID 25637283 DOI: 10.1016/J.Molonc.2015.01.002 |
0.386 |
|
| 2015 |
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, ... ... Tyner JW, et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine. 21: 71-5. PMID 25485910 DOI: 10.1038/Nm.3751 |
0.437 |
|
| 2015 |
Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75: 880-91. PMID 25432174 DOI: 10.1158/0008-5472.Can-14-0573 |
0.591 |
|
| 2015 |
Huang TC, Cutler J, Bharne S, Zhong J, Weinstock D, Tyner J, Gojo I, Civin C, Pandey A. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target. Leukemia & Lymphoma. 56: 1524-7. PMID 25213184 DOI: 10.3109/10428194.2014.963076 |
0.463 |
|
| 2015 |
Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene. 34: 2991-9. PMID 25109334 DOI: 10.1038/Onc.2014.243 |
0.571 |
|
| 2015 |
Leonard JT, Spurgeon SEF, Traer EA, Hayes-Lattin BM, Loriaux M, Tyner J, Druker BJ, Chang BH. The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors. Journal of Clinical Oncology. 33: 7073-7073. DOI: 10.1200/Jco.2015.33.15_Suppl.7073 |
0.516 |
|
| 2015 |
Carey A, Cleary MM, Edwards DK, Eide CA, Traer E, McWeeney SK, Tyner JW, Bagby GC, Druker BJ, Agarwal A. The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia Blood. 126: 866-866. DOI: 10.1182/Blood.V126.23.866.866 |
0.527 |
|
| 2015 |
Kurtz SE, Traer E, Martinez J, Park A, Wagner J, Pandya R, Bolosky W, Druker BJ, Tyner JW. Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens Blood. 126: 865-865. DOI: 10.1182/Blood.V126.23.865.865 |
0.581 |
|
| 2015 |
Sweeney T, Spurgeon SE, Tyner JW, Agarwal A, Ho H, Traer E, Lee P, Chantry D, Druker BJ, Loriaux M. Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL Blood. 126: 4439-4439. DOI: 10.1182/Blood.V126.23.4439.4439 |
0.574 |
|
| 2015 |
Edwards DK, Rofelty A, Agarwal A, Kurtz SE, Traer E, Lee P, Chantry D, Loriaux M, Druker BJ, McWeeney SK, Tyner JW. CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes Blood. 126: 3824-3824. DOI: 10.1182/Blood.V126.23.3824.3824 |
0.579 |
|
| 2015 |
Watanabe-Smith KM, Tognon CE, Tyner JW, Druker BJ, Agarwal A. A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes Blood. 126: 3670-3670. DOI: 10.1182/Blood.V126.23.3670.3670 |
0.577 |
|
| 2015 |
Chow M, MacManiman JD, Bicocca VT, Gao L, Alumkal JA, Chang BH, Tyner JW. ROR1 Protein Expression Is Regulated By UHRF1 in t(1;19) Pre B-Cell ALL Blood. 126: 3648-3648. DOI: 10.1182/Blood.V126.23.3648.3648 |
0.399 |
|
| 2015 |
Zhang Q, Pan R, Han L, Shi C, Kurtz SE, Mu H, Ma H, Andreeff M, Leverson J, Tyner JW, Mi Y, Konopleva M. Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models Blood. 126: 328-328. DOI: 10.1182/Blood.V126.23.328.328 |
0.427 |
|
| 2015 |
Carey A, Garg S, Cleary MM, Edwards DK, Loriaux M, Winski SL, Cable L, Tyner JW, Agarwal A. p38MAPK Inhibition Blocks Inflammatory Signaling in Acute Myeloid Leukemia Blood. 126: 2603-2603. DOI: 10.1182/Blood.V126.23.2603.2603 |
0.428 |
|
| 2015 |
Zhang H, Watanabe-Smith KM, Bottomly D, Wilmot B, McWeeney SK, Kantarjian HM, Ho J, Davis J, Pond B, Borthakur G, Ramachandran A, Cortes JE, Collins R, Tyner JW. Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib Blood. 126: 2468-2468. DOI: 10.1182/Blood.V126.23.2468.2468 |
0.424 |
|
| 2015 |
Savage SL, Eide CA, Concannon KF, Bottomly D, Wilmot B, McWeeney SK, Maxson JE, Tyner JW, Tognon CE, Druker BJ. Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia Blood. 126: 2461-2461. DOI: 10.1182/Blood.V126.23.2461.2461 |
0.635 |
|
| 2015 |
Lamble A, Kosaka Y, Lo P, Huang F, Sasser K, Tognon CE, Loriaux M, Tyner JW, Druker BJ, Lind EF. Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia Blood. 126: 1374-1374. DOI: 10.1182/Blood.V126.23.1374.1374 |
0.527 |
|
| 2015 |
Kurtz SE, Bottomly D, Wilmot B, McWeeney SK, Rice W, Howell SB, Vellanki A, Druker BJ, Tyner JW. Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level Blood. 126: 1358-1358. DOI: 10.1182/Blood.V126.23.1358.1358 |
0.551 |
|
| 2015 |
Leonard J, Rowley J, Hayes-Lattin B, Tyner JW, Loriaux M, Druker BJ, Chang BH. Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax) Blood. 126: 1329-1329. DOI: 10.1182/Blood.V126.23.1329.1329 |
0.569 |
|
| 2015 |
Newell LF, Holtan SG, Rosenzweig J, Yates J, Garbati M, Rathbun RK, Keeble W, Tyner JW, Burd I, Bagby GC. Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes Blood. 126: 1006-1006. DOI: 10.1182/Blood.V126.23.1006.1006 |
0.33 |
|
| 2015 |
Martinez J, Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner J, Wong M, Druker B. Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML Cancer Research. 75: 984-984. DOI: 10.1158/1538-7445.Am2015-984 |
0.555 |
|
| 2015 |
Leonard JT, Traer E, Hayes-Lattin B, Tyner J, Druker B, Chang BH. Targeting BCL-2 and BCR-Abl Activity in Ph+ALL Biology of Blood and Marrow Transplantation. 21: S190. DOI: 10.1016/J.Bbmt.2014.11.288 |
0.462 |
|
| 2014 |
Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 3: 67-9. PMID 25180155 DOI: 10.1016/J.Lrr.2014.07.002 |
0.543 |
|
| 2014 |
Kim MS, Zhong Y, Yachida S, Rajeshkumar NV, Abel ML, Marimuthu A, Mudgal K, Hruban RH, Poling JS, Tyner JW, Maitra A, Iacobuzio-Donahue CA, Pandey A. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Molecular & Cellular Proteomics : McP. 13: 2803-11. PMID 24895378 DOI: 10.1074/Mcp.M114.038547 |
0.402 |
|
| 2014 |
Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/Pnas.1403608111 |
0.544 |
|
| 2014 |
Yao H, Goldman DC, Nechiporuk T, Kawane S, McWeeney SK, Tyner JW, Fan G, Kerenyi MA, Orkin SH, Fleming WH, Mandel G. Corepressor Rcor1 is essential for murine erythropoiesis. Blood. 123: 3175-84. PMID 24652990 DOI: 10.1182/Blood-2013-11-538678 |
0.36 |
|
| 2014 |
Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 28: 1978-87. PMID 24637335 DOI: 10.1038/Leu.2014.109 |
0.341 |
|
| 2014 |
Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database : the Journal of Biological Databases and Curation. 2014: bau007. PMID 24573880 DOI: 10.1093/Database/Bau007 |
0.35 |
|
| 2014 |
Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2092-103. PMID 24436473 DOI: 10.1158/1078-0432.Ccr-13-2575 |
0.579 |
|
| 2014 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 123: 1516-24. PMID 24408322 DOI: 10.1182/Blood-2013-07-518381 |
0.579 |
|
| 2014 |
Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. The Journal of Biological Chemistry. 289: 5820-7. PMID 24403076 DOI: 10.1074/Jbc.M113.508440 |
0.508 |
|
| 2014 |
Carey A, Edwards D, Eide CA, Traer E, Tyner JW, Bagby GC, Druker BJ, Agarwal A. Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic Cellular Growth and Disease Progression in Primary Human Cells and Murine Models of Acute Myeloid leukemia Blood. 124: 702-702. DOI: 10.1182/Blood.V124.21.702.702 |
0.568 |
|
| 2014 |
Siegel MB, Davare MA, Liu SQ, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma Blood. 124: 4702-4702. DOI: 10.1182/Blood.V124.21.4702.4702 |
0.552 |
|
| 2014 |
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Pomicter AD, Iovino AJ, Reynolds KR, Eiring AM, Zabriskie MS, Kronenberg Z, Tyner JW, Dalley B, Dao KT, O'Hare T, Yandell M, et al. Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival Blood. 124: 4637-4637. DOI: 10.1182/Blood.V124.21.4637.4637 |
0.531 |
|
| 2014 |
Eide CA, Savage SL, Agarwal A, Bottomly D, Wilmot B, McWeeney SK, Kurtz SE, O'Hare T, Deininger MW, Loriaux MM, Tognon CE, Tyner JW, Druker BJ. Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors Blood. 124: 4514-4514. DOI: 10.1182/Blood.V124.21.4514.4514 |
0.603 |
|
| 2014 |
Maxson JE, Melissa AL, Wang J, Deng X, Luty SB, Sun H, Gorenstein J, Middleton R, Gray NS, Druker BJ, Tyner JW. Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations Blood. 124: 435-435. DOI: 10.1182/Blood.V124.21.435.435 |
0.584 |
|
| 2014 |
Lenz K, Thompson S, Goloviznina NA, Huan J, LaTocha DH, Druker BJ, Tyner JW, Kurre P, Chang BH. Dasatinib Shows Therapeutic Potential in the Murine Xenograft Model for TCF3 rearranged Acute Lymphoblastic Leukemia Blood. 124: 3718-3718. DOI: 10.1182/Blood.V124.21.3718.3718 |
0.559 |
|
| 2014 |
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, ... ... Tyner JW, et al. GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition Blood. 124: 3567-3567. DOI: 10.1182/Blood.V124.21.3567.3567 |
0.504 |
|
| 2014 |
Geng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan LN, ... ... Tyner JW, et al. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood. 124: 284-284. DOI: 10.1182/Blood.V124.21.284.284 |
0.442 |
|
| 2014 |
Agarwal A, Carey A, Traer E, Tyner J, Bagby GC, Druker BJ. Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells Cancer Research. 74: 5248-5248. DOI: 10.1158/1538-7445.Am2014-5248 |
0.552 |
|
| 2014 |
Maxson J, Luty S, MacManiman J, Savage S, Abel M, Bahamadi S, Druker B, Tyner J. Abstract 2760: CSF3R ligand-independent mutations found in chronic neutrophilic leukemia have altered O-linked glycosylation Cancer Research. 74: 2760-2760. DOI: 10.1158/1538-7445.Am2014-2760 |
0.535 |
|
| 2013 |
Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B. Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5: 103. PMID 24286512 DOI: 10.1186/Gm509 |
0.486 |
|
| 2013 |
Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 110: 19519-24. PMID 24218589 DOI: 10.1073/Pnas.1319583110 |
0.586 |
|
| 2013 |
Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 122: 3628-31. PMID 24081659 DOI: 10.1182/Blood-2013-06-509976 |
0.563 |
|
| 2013 |
Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.Mcr-12-0598 |
0.476 |
|
| 2013 |
Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway Leukemia. 27: 2094-2096. PMID 23900138 DOI: 10.1038/Leu.2013.228 |
0.567 |
|
| 2013 |
Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 122: 1707-11. PMID 23896413 DOI: 10.1182/Blood-2013-05-500959 |
0.456 |
|
| 2013 |
Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. Journal of Cancer Research and Clinical Oncology. 139: 1507-14. PMID 23824064 DOI: 10.1007/S00432-013-1465-6 |
0.344 |
|
| 2013 |
Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC. The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell. 24: 2582-92. PMID 23783032 DOI: 10.1091/Mbc.E13-03-0144 |
0.514 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, ... ... Tyner JW, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/Nejmoa1214514 |
0.536 |
|
| 2013 |
Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 27: 1870-3. PMID 23604229 DOI: 10.1038/Leu.2013.122 |
0.371 |
|
| 2013 |
O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, ... Tyner JW, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Research. 73: 3356-70. PMID 23576564 DOI: 10.1158/0008-5472.Can-12-3904 |
0.603 |
|
| 2013 |
Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Translational Oncology. 6: 158-68. PMID 23544168 DOI: 10.1593/Tlo.12307 |
0.527 |
|
| 2013 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discovery. 3: 564-77. PMID 23471820 DOI: 10.1158/2159-8290.Cd-12-0504 |
0.579 |
|
| 2013 |
Dao KH, Tyner JW. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1309-11. PMID 23382113 DOI: 10.1158/1078-0432.Ccr-12-3934 |
0.418 |
|
| 2013 |
Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK. HitWalker: variant prioritization for personalized functional cancer genomics. Bioinformatics (Oxford, England). 29: 509-10. PMID 23303510 DOI: 10.1093/Bioinformatics/Btt003 |
0.462 |
|
| 2013 |
Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 344: 378-87. PMID 23220742 DOI: 10.1124/Jpet.112.200832 |
0.578 |
|
| 2013 |
Kulesz-Martin M, Lagowski J, Olson S, Wortham A, West T, Thomas G, Ryan CW, Tyner JW. A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma Cancer Biology and Therapy. 14: 95-99. PMID 23192268 DOI: 10.4161/Cbt.22960 |
0.387 |
|
| 2013 |
Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.Can-12-1906 |
0.592 |
|
| 2013 |
Agarwal A, Meckenzie RJ, Carey A, Davare M, Eide CA, Watanabe-Smith K, Braziel RM, Tyner JW, Bagby GC, Druker BJ. Critical Role Of Interleukin Receptor Signaling In Acute Myeloid Leukemia Identified Using An RNAi Functional Screen Blood. 122: 473-473. DOI: 10.1182/Blood.V122.21.473.473 |
0.615 |
|
| 2013 |
Eide CA, Savage SL, Bryant J, Agarwal A, Bottomly D, Wilmot B, McWeeney SK, O'Hare T, Deininger MW, Loriaux MM, Tognon CE, Tyner JW, Druker BJ. Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors Blood. 122: 3994-3994. DOI: 10.1182/Blood.V122.21.3994.3994 |
0.619 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap JB, English I, Martinez J, Tyner JW, Wong M, Druker BJ. FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib Blood. 122: 3983-3983. DOI: 10.1182/Blood.V122.21.3983.3983 |
0.595 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Luty SB, Abel M, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Collins RH, Pond JB, Goueli B, ... ... Tyner JW, et al. The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization Blood. 122: 270-270. DOI: 10.1182/Blood.V122.21.270.270 |
0.558 |
|
| 2013 |
Huang T, Bharne SS, Cutler J, Zhong J, Weinstock DM, Tyner JW, Civin CI, Pandey A. Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target Blood. 122: 2667-2667. DOI: 10.1182/Blood.V122.21.2667.2667 |
0.451 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap JB, English I, Martinez J, Kovacsovics TJ, Tyner JW, Wong M, Druker BJ. FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance Blood. 122: 2541-2541. DOI: 10.1182/Blood.V122.21.2541.2541 |
0.603 |
|
| 2013 |
Agarwal A, Meckenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias Blood. 122: 2511-2511. DOI: 10.1182/Blood.V122.21.2511.2511 |
0.626 |
|
| 2013 |
Yoda A, Adelmant G, Shindoh N, Chapuy B, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Tyner JW, Gotlib J, Deininger MW, Turley S, et al. The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies Blood. 122: 2510-2510. DOI: 10.1182/Blood.V122.21.2510.2510 |
0.452 |
|
| 2013 |
Maxson JE, Fleischman AG, Luty SB, Royer LR, Agarwal A, Loriaux MM, Druker BJ, Tyner JW. CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia Blood. 122: 223-223. DOI: 10.1182/Blood.V122.21.223.223 |
0.53 |
|
| 2013 |
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, Tyner J, Wong M, Druker B. Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML. Cancer Research. 73: 4971-4971. DOI: 10.1158/1538-7445.Am2013-4971 |
0.594 |
|
| 2013 |
Agarwal A, MacKenzie R, Braziel R, Tyner JW, Druker BJ. Abstract 2333: Functional RNAi screen identifies novel cytokine and growth factor receptors critical for the growth of leukemia patient samples. Cancer Research. 73: 2333-2333. DOI: 10.1158/1538-7445.Am2013-2333 |
0.589 |
|
| 2013 |
Maxson J, Gotlib J, Pollyea D, Fleischman A, Eide C, Bottomly D, Wilmot B, McWeeney S, Tognon C, Pond JB, Collins R, Deininger M, Chang B, Loriaux M, Druker B, ... Tyner J, et al. Abstract 2282: Rapid identification of targetable CSF3R mutations that define neutrophilic leukemia by combining functional and genomic screens. Cancer Research. 73: 2282-2282. DOI: 10.1158/1538-7445.Am2013-2282 |
0.606 |
|
| 2013 |
Chien W, Lee KL, Sun Q, Wuensche P, Sudo M, Poellinger L, Tyner JW, Yang H, Koeffler HP. Abstract 1291: Identification of penfluridol as potential treatment for pancreatic cancer cells. Cancer Research. 73: 1291-1291. DOI: 10.1158/1538-7445.Am2013-1291 |
0.383 |
|
| 2013 |
Yoda A, Adelmant G, Shindoh N, Chapuy B, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Tyner JW, Gotlib J, Deininger MW, Turley S, et al. Abstract PR07: Novel oncogenic mutations in the beta subunit of heteromeric G-proteins identified by functional cDNA library screening. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr07 |
0.454 |
|
| 2013 |
Dao K, Rotelli M, Brown B, Yates J, Rantala J, Tognon C, Tyner J, Druker B, Bagby G. The PI3K/Akt1 pathway enhances steady state levels of FANCL Experimental Hematology. 41. DOI: 10.1016/J.Exphem.2013.05.165 |
0.514 |
|
| 2012 |
Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/J.Ccr.2012.08.027 |
0.561 |
|
| 2012 |
Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/J.Bbrc.2012.08.092 |
0.553 |
|
| 2012 |
van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood. 120: 2853-63. PMID 22915648 DOI: 10.1182/Blood-2012-02-413252 |
0.434 |
|
| 2012 |
Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD, Koeffler HP. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncology Letters. 3: 807-815. PMID 22740998 DOI: 10.3892/Ol.2012.579 |
0.403 |
|
| 2012 |
Fleischman AG, Tyner JW. JAK2 V617F down-modulates MPL. Blood. 119: 4579-80. PMID 22596167 DOI: 10.1182/Blood-2012-03-417261 |
0.313 |
|
| 2012 |
Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A, Neff TL, Tyner JW, Dunlap J, Corless CL, Fan G. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia. 26: 2144-6. PMID 22425895 DOI: 10.1038/Leu.2012.74 |
0.359 |
|
| 2012 |
Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, ... ... Tyner JW, et al. TSLP signaling network revealed by SILAC-based phosphoproteomics. Molecular & Cellular Proteomics : McP. 11: M112.017764. PMID 22345495 DOI: 10.1074/Mcp.M112.017764 |
0.405 |
|
| 2012 |
Anur P, Yates J, Garbati MR, Vanderwerf S, Keeble W, Rathbun K, Hays LE, Tyner JW, Svahn J, Cappelli E, Dufour C, Bagby GC. p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes. Blood. 119: 1992-2002. PMID 22234699 DOI: 10.1182/Blood-2011-06-354647 |
0.351 |
|
| 2012 |
Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatric Blood & Cancer. 59: 576-9. PMID 22038978 DOI: 10.1002/Pbc.23383 |
0.517 |
|
| 2012 |
Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 26: 623-32. PMID 21960246 DOI: 10.1038/Leu.2011.249 |
0.576 |
|
| 2012 |
Chang BH, Jemal A, Tyner J, Thayer M, Muschen M, Druker BJ. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology. 30: 9555-9555. DOI: 10.1200/Jco.2012.30.15_Suppl.9555 |
0.539 |
|
| 2012 |
Geng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner JW, Chang BH, Titz B, Buchner M, Hurtz C, Graeber TG, Druker BJ, Paietta E, Melnick A, Willman CL, Carroll WL, et al. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood. 120: 528-528. DOI: 10.1182/Blood.V120.21.528.528 |
0.564 |
|
| 2012 |
O'Farrell M, Ventura R, Tai A, Tyner JW, Loriaux MM, Mahadevan D, Morales C, Brown SD, Matthews DJ. Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies. Blood. 120: 2907-2907. DOI: 10.1182/Blood.V120.21.2907.2907 |
0.467 |
|
| 2012 |
Maxson JE, Gotlib J, Fleischman AG, Eide CA, Bottomly D, Wilmot B, McWeeney S, Tognon C, Loriaux MM, Druker BJ, Tyner JW. A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib. Blood. 120: 2412-2412. DOI: 10.1182/Blood.V120.21.2412.2412 |
0.627 |
|
| 2012 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover JM, Chang BH, Yost AJ, Weng AP, Ma W, Tatarek J, Fleischman AG, Ahn Y, Yang Y, Zhou W, Neuberg DS, et al. TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia Blood. 120: 1470-1470. DOI: 10.1182/Blood.V120.21.1470.1470 |
0.543 |
|
| 2012 |
Huan J, Hornick N, Lenz K, Goloviznina NA, Skinner AM, Tyner JW, Roberts CT, Kurre P. AML Exosomes Regulate Stromal Bystander Cells and Provide a Novel RNA Biomarker Platform Blood. 120: 1378-1378. DOI: 10.1182/Blood.V120.21.1378.1378 |
0.371 |
|
| 2012 |
Agarwal A, MacKenzie R, Braziel RM, Tyner JW, Druker BJ. Functional RNAi Screen Identifies Novel Cytokine and Growth Factor Receptors Critical for Leukemia Cell Growth Blood. 120: 1308-1308. DOI: 10.1182/Blood.V120.21.1308.1308 |
0.614 |
|
| 2012 |
Dao KT, Rotelli MD, Yates JE, Brown B, Rantala J, Rathbun K, Tyner JW, Druker BJ, Bagby GC. Regulation of FANCL by Glycogen Synthase Kinase-3beta Links the Fanconi anemia pathway to Self Renewal and Survival Signals Blood. 120: 1263-1263. DOI: 10.1182/Blood.V120.21.1263.1263 |
0.512 |
|
| 2011 |
Tyner JW. Phosphoproteomics microarray screen reveals novel interaction between MPL and Tensin2: implications for biology, disease and therapeutics. Cell Cycle (Georgetown, Tex.). 10: 2621-2. PMID 21829102 DOI: 10.4161/Cc.10.16.16391 |
0.419 |
|
| 2011 |
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.Can-10-3224 |
0.596 |
|
| 2011 |
Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics. 10: 1028-35. PMID 21482694 DOI: 10.1158/1535-7163.Mct-10-1044 |
0.584 |
|
| 2011 |
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117: 591-4. PMID 20959606 DOI: 10.1182/Blood-2010-03-275305 |
0.585 |
|
| 2011 |
Fleischman AG, Sanda T, Gutierrez A, Luty SB, Willis SG, Look AT, Druker BJ, Tyner JW. Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice Blood. 118: 74-74. DOI: 10.1182/Blood.V118.21.74.74 |
0.581 |
|
| 2011 |
Prins RC, Spurgeon S, Tyner JW, Fletcher LB, Jemal A, Bryant JA, Burke RT, Chang BH, Kovacsovics T, Druker BJ, Loriaux MM. CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies, Blood. 118: 3512-3512. DOI: 10.1182/Blood.V118.21.3512.3512 |
0.621 |
|
| 2011 |
Jemal A, Tyner JW, Thayer M, Muschen M, Druker BJ, Chang BH. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia Blood. 118: 2490-2490. DOI: 10.1182/Blood.V118.21.2490.2490 |
0.577 |
|
| 2011 |
Yu Q, Eiring AM, Zabriskie MS, Khorashad J, Anderson DJ, Bryant JA, Loriaux MM, Tyner JW, O'Hare T, Deininger MW. Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib Blood. 118: 2481-2481. DOI: 10.1182/Blood.V118.21.2481.2481 |
0.435 |
|
| 2011 |
Bicocca VT, Chang BH, Muschen M, Druker BJ, Tyner JW. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia Blood. 118: 2466-2466. DOI: 10.1182/Blood.V118.21.2466.2466 |
0.622 |
|
| 2011 |
Hornick N, Huan J, Tyner JW, Kurre P. Flt3 Kinase Regulates Microvesicle Transfer of miRNA Between AML and Stromal Cells Blood. 118: 1492-1492. DOI: 10.1182/Blood.V118.21.1492.1492 |
0.383 |
|
| 2011 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover J, Chang BH, Willis SG, Zhou W, Gray NS, Staudt LM, Druker BJ, Look AT. Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia Cancer Research. 71: 2809-2809. DOI: 10.1158/1538-7445.Am2011-2809 |
0.58 |
|
| 2010 |
Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Research. 70: 6233-7. PMID 20670955 DOI: 10.1158/0008-5472.Can-10-0429 |
0.506 |
|
| 2010 |
Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115: 5232-40. PMID 20385788 DOI: 10.1182/Blood-2009-05-223727 |
0.604 |
|
| 2010 |
Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 24: 226-9. PMID 19759561 DOI: 10.1038/Leu.2009.196 |
0.499 |
|
| 2010 |
Bicocca V, Chang BH, Muschen M, Druker BJ, Tyner JW. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia Blood. 116: 539-539. DOI: 10.1182/Blood.V116.21.539.539 |
0.625 |
|
| 2010 |
Chang BH, Tyner JW, Jemal A, Thayer M, Druker BJ. RNAi Identifies Survivin as a Potential Target for Therapy In Pediatric Acute Lymphoblastic Leukemia Blood. 116: 5108-5108. DOI: 10.1182/Blood.V116.21.5108.5108 |
0.577 |
|
| 2010 |
Fletcher LB, Spurgeon S, Tyner JW, Druker BJ, Loriaux MM. A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells Blood. 116: 3594-3594. DOI: 10.1182/Blood.V116.21.3594.3594 |
0.609 |
|
| 2010 |
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover JM, Chang BH, Willis SG, Staudt LM, Druker BJ, Look AT. Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia Blood. 116: 3155-3155. DOI: 10.1182/Blood.V116.21.3155.3155 |
0.568 |
|
| 2010 |
Tyner JW, Tardi P, Mayer L, Fletcher LB, Spurgeon S, Kovacsovics T, Loriaux MM. Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells Blood. 116: 2886-2886. DOI: 10.1182/Blood.V116.21.2886.2886 |
0.461 |
|
| 2010 |
Spurgeon S, Fletcher LB, Tyner JW, Druker BJ, Pandey A, Sinha U, Loriaux MM. P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations Blood. 116: 2839-2839. DOI: 10.1182/Blood.V116.21.2839.2839 |
0.576 |
|
| 2010 |
Tyner JW, Spurgeon S, Fletcher LB, Yang W, Kovacsovics T, Druker BJ, Loriaux MM. A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias Blood. 116: 2754-2754. DOI: 10.1182/Blood.V116.21.2754.2754 |
0.63 |
|
| 2010 |
Tyner JW, Sanda T, Gutierrez A, Glover JM, Chang BH, Willis SG, Ahn Y, Look AT, Druker BJ. RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia Blood. 116: 1001-1001. DOI: 10.1182/Blood.V116.21.1001.1001 |
0.603 |
|
| 2009 |
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16: 401-12. PMID 19878872 DOI: 10.1016/J.Ccr.2009.09.028 |
0.605 |
|
| 2009 |
Tyner J, Druker BJ. RNAi screen for therapeutic target in leukemia. Cell Cycle (Georgetown, Tex.). 8: 2144. PMID 19587534 |
0.398 |
|
| 2009 |
Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 106: 8695-700. PMID 19433805 DOI: 10.1073/Pnas.0903233106 |
0.567 |
|
| 2009 |
Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM. Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia. 23: 1345-8. PMID 19340004 DOI: 10.1038/Leu.2009.66 |
0.584 |
|
| 2009 |
Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113: 1749-55. PMID 19075190 DOI: 10.1182/Blood-2008-04-152157 |
0.465 |
|
| 2009 |
Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia. 23: 406-9. PMID 18615102 DOI: 10.1038/Leu.2008.187 |
0.52 |
|
| 2009 |
Tyner J, Druker BJ. RNAi screen for therapeutic target in leukemia Cell Cycle. 8: 2143-2144. DOI: 10.4161/Cc.8.14.9119 |
0.476 |
|
| 2009 |
Tyner JW, Fletcher L, Yang W, Oh ST, Gotlib JR, Deininger MW, Druker BJ, Loriaux M. Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. Blood. 114: 708-708. DOI: 10.1182/Blood.V114.22.708.708 |
0.622 |
|
| 2009 |
Tyner JW, Loriaux M, Willis SG, Chang BH, Bicocca VT, Oh ST, Hollink IH, Segers S, DenBoer ML, van den Heuvel-Eibrink MM, Zwaan CM, Gotlib JR, Deininger M, Druker BJ. RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. Blood. 114: 3978-3978. DOI: 10.1182/Blood.V114.22.3978.3978 |
0.575 |
|
| 2009 |
Praveen A, Tyner JW, Vanderwerff S, Keeble W, Bagby GC. A High Throughput Small Molecule Screening Method for Fanconi Anemia. Blood. 114: 3191-3191. DOI: 10.1182/Blood.V114.22.3191.3191 |
0.451 |
|
| 2008 |
Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. Plos One. 3: e3593. PMID 18974832 DOI: 10.1371/Journal.Pone.0003593 |
0.606 |
|
| 2008 |
Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature Medicine. 14: 633-40. PMID 18488036 DOI: 10.1038/Nm1770 |
0.65 |
|
| 2008 |
O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences of the United States of America. 105: 5507-12. PMID 18367669 DOI: 10.1073/Pnas.0800587105 |
0.493 |
|
| 2008 |
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/Blood-2007-07-101394 |
0.535 |
|
| 2008 |
Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 111: 2238-45. PMID 18025156 DOI: 10.1182/Blood-2007-06-097253 |
0.577 |
|
| 2008 |
Bumm TG, Tyner JW, Deininger J, Loriaux M, VanDyke J, Druker BJ, Burns CJ, Fantino3 E, Deininger MW. Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD Blood. 112: 856-856. DOI: 10.1182/Blood.V112.11.856.856 |
0.557 |
|
| 2008 |
Tyner JW, Loriaux M, Willis SG, Chang B, Bicocca VT, Oh S, Hollink IH, Segers S, den Boer ML, Zwaan CM, Gotlib JR, Deininger MW, Druker BJ. RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients Blood. 112: 758-758. DOI: 10.1182/Blood.V112.11.758.758 |
0.583 |
|
| 2008 |
Tyner JW, Erickson H, Oh S, Gotlib JR, Deininger MW, Druker BJ, Loriaux M. Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis Blood. 112: 2519-2519. DOI: 10.1182/Blood.V112.11.2519.2519 |
0.623 |
|
| 2007 |
Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 110: 323-33. PMID 17360941 DOI: 10.1182/Blood-2006-10-052282 |
0.599 |
|
| 2007 |
O’Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib. Blood. 110: 535-535. DOI: 10.1182/Blood.V110.11.535.535 |
0.485 |
|
| 2007 |
Tyner JW, Willis S, Deininger MW, Druker BJ. RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients. Blood. 110: 208-208. DOI: 10.1182/Blood.V110.11.208.208 |
0.606 |
|
| 2007 |
Agarwal A, Eide CA, Harlow A, Tyner JW, Mauro MJ, Corless CL, Heinrich MC, Druker BJ, Deininger MW. An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia. Blood. 110: 1006-1006. DOI: 10.1182/Blood.V110.11.1006.1006 |
0.597 |
|
| 2006 |
Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 20: 2008-14. PMID 16990784 DOI: 10.1038/Sj.Leu.2404374 |
0.41 |
|
| 2006 |
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/J.Ccr.2006.06.002 |
0.597 |
|
| 2006 |
Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel AC, Patterson GA, Castro M, Spoor MS, You Y, Brody SL, Holtzman MJ. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. The Journal of Clinical Investigation. 116: 309-21. PMID 16453019 DOI: 10.1172/Jci25167 |
0.698 |
|
| 2006 |
Tyner JW, Eide CA, Stoffregen EP, Loriaux M, Willis SG, Gattermann N, Kovacsovics T, Druker BJ, Deininger MW. Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia. Blood. 108: 3606-3606. DOI: 10.1182/Blood.V108.11.3606.3606 |
0.567 |
|
| 2006 |
O’Hare T, Eide CA, Tyner JW, Wong MJ, Smith CA, Corbin AS, Buchanan S, Jessen KA, Tang C, Holme K, Burley SK, Deininger MW. Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393. Blood. 108: 1373-1373. DOI: 10.1182/Blood.V108.11.1373.1373 |
0.46 |
|
| 2005 |
Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Medicine. 11: 1180-7. PMID 16208318 DOI: 10.1038/Nm1303 |
0.651 |
|
| 2005 |
Holtzman MJ, Tyner JW, Kim EY, Lo MS, Patel AC, Shornick LP, Agapov E, Zhang Y. Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2: 132-40. PMID 16113481 DOI: 10.1513/pats.200502-015AW |
0.747 |
|
| 2005 |
Holtzman MJ, Kim EY, Lo MS, Tyner JW, Shornick LP, Sumino KC, Zhang Y. Defining and adjusting divergent host responses to viral infection. Immunologic Research. 32: 123-41. PMID 16106064 DOI: 10.1385/Ir:32:1-3:123 |
0.754 |
|
| 2004 |
Holtzman MJ, Shornick LP, Grayson MH, Kim EY, Tyner JW, Patel AC, Agapov E, Zhang Y. "Hit-and-run" effects of paramyxoviruses as a basis for chronic respiratory disease. The Pediatric Infectious Disease Journal. 23: S235-45. PMID 15577579 DOI: 10.1097/01.Inf.0000144674.24802.C1 |
0.646 |
|
| 2004 |
TYNER J. Chemokine CCL5 signals required for survival during viral infection*1 Journal of Allergy and Clinical Immunology. 113: S49. DOI: 10.1016/J.Jaci.2003.12.138 |
0.316 |
|
| 2003 |
O'Sullivan MP, Tyner JW, Holtzman MJ. Apoptosis in the airways: another balancing act in the epithelial program. American Journal of Respiratory Cell and Molecular Biology. 29: 3-7. PMID 12821445 DOI: 10.1165/Rcmb.F273 |
0.551 |
|
| 2002 |
Holtzman MJ, Morton JD, Shornick LP, Tyner JW, O'Sullivan MP, Antao A, Lo M, Castro M, Walter MJ. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. Physiological Reviews. 82: 19-46. PMID 11773608 DOI: 10.1152/Physrev.00020.2001 |
0.702 |
|
| Show low-probability matches. |